Description: Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Home Page: www.leespharm.com
Building 20E
Sha Tin,
Hong Kong
Phone:
852 2314 1282
Officers
| Name | Title |
|---|---|
| Ms. Siu Fong Lee | Chairman & Compliance Officer |
| Ms. Wanee Leelalertsuphakun | MD, Chief Marketing & Sales Officer and Exec. Director |
| Dr. Xiaoyi Li Ph.D. | Sr. Adviser & Non-Exec. Director |
| Mr. Yiu Ming Chow | Group CFO & Company Sec. |
| Mr. Yueshen Chen | Chief Operating Officer |
| Mr. Zhongyu Jiao | Chief Officer of Enterprise Devel. Department of the Group |
| Mr. Tsui Victor Kailok | Group Chief Manufacturing Officer |
| Mr. Yuanjue Sun | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0002 |
| Price-to-Sales TTM: | 0.1042 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1319 |